NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Clinical safety rating: safe
Can reduce absorption of drugs requiring gastric pH for absorption (eg ketoconazole) May increase risk of Clostridium difficile-associated diarrhea and bone fractures with long-term use.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Esomeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase pump in gastric parietal cells, decreasing gastric acid secretion.
| Metabolism | Naproxen is primarily metabolized by hepatic CYP1A2 and CYP2C9 to 6-O-desmethylnaproxen and other metabolites. Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4 to hydroxy, desmethyl, and sulfone metabolites. |
| Excretion | Naproxen: ~95% renal (as unchanged drug and conjugates), ~5% fecal. Esomeprazole: ~80% renal (as metabolites), ~20% fecal. |
| Half-life | Naproxen: ~12-17 hours (allows twice-daily dosing). Esomeprazole: ~1-1.5 hours (no accumulation). |
| Protein binding | Naproxen: >99% bound to albumin. Esomeprazole: 97% bound to albumin. |
| Volume of Distribution | Naproxen: 0.16 L/kg (low, mainly in plasma). Esomeprazole: 0.22 L/kg (moderate, extracellular fluid). |
| Bioavailability | Naproxen: ~95% oral. Esomeprazole: ~64% oral (first-pass metabolism). |
| Onset of Action | Naproxen: 1-2 hours oral (analgesic effect). Esomeprazole: ~1 hour oral (acid suppression). |
| Duration of Action | Naproxen: 8-12 hours (immediate release). Esomeprazole: ~24 hours (once daily acid suppression). |
| Molecular Weight | Naproxen: 230.26 Da; Esomeprazole magnesium: 345.42 Da (anhydrous free acid equivalent); combined drug as a fixed-dose combination. |
One tablet (naproxen 500 mg / esomeprazole 20 mg) orally twice daily.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | Contraindicated in patients with creatinine clearance <30 mL/min. For CrCl 30-89 mL/min, no dose adjustment; use with caution. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): avoid use. |
| Pediatric use | Not recommended for patients <18 years of age; safety and efficacy not established. |
| Geriatric use | Use the lowest effective dose for the shortest duration. Consider renal function; avoid in CrCl <30 mL/min. Monitor for GI bleeding and renal impairment. |
| 1st trimester | Avoid during first trimester unless absolutely necessary. NSAIDs may increase risk of spontaneous abortion and congenital anomalies. |
| 2nd trimester | Use only if clearly needed. May cause oligohydramnios and premature closure of ductus arteriosus. |
| 3rd trimester | Contraindicated in third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
Clinical note
Can reduce absorption of drugs requiring gastric pH for absorption (eg ketoconazole) May increase risk of Clostridium difficile-associated diarrhea and bone fractures with long-term use.
| FDA category | Animal |
| Placental transfer | Both components cross the placenta; naproxen highly protein-bound but transfers, esomeprazole likely crosses. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Common Effects | erosive esophagitis |
| Serious Effects |
History of allergic reaction to aspirin or other NSAIDsActive peptic ulcer diseaseSevere renal impairment (CrCl <30 mL/min)Severe hepatic impairmentThird trimester of pregnancyHistory of GI bleeding or perforation related to NSAIDsConcomitant use of other NSAIDs including COX-2 inhibitors
| Precautions | Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; elevation of liver enzymes; renal toxicity; hypertension; exacerbation of asthma; anemia; fluid retention; masking of inflammation; photosensitivity; risk of Clostridium difficile-associated diarrhea; hypomagnesemia; vitamin B12 deficiency; osteoporosis-related fractures; decreased gastric acidity leading to increased risk of gastrointestinal infections. |
Loading safety data…
| Breastfeeding |
| Both naproxen and esomeprazole transfer into breast milk in low amounts. Naproxen has a long half-life and may accumulate in nursing infants with prolonged use. Avoid use in breastfeeding women, especially in infants with potential sensitivity or if long-term use, due to risk of adverse effects (e.g., gastrointestinal, renal). |
| Lactation Rating | L3 - Moderately Safe (probably compatible but avoid if possible) |
| Teratogenic Risk | First trimester: NSAID use associated with increased risk of spontaneous abortion and cardiac defects (relative risk 1.8–2.0). Second trimester: Generally low risk, but avoid prolonged use. Third trimester: NSAIDs (naproxen) cause premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment; esomeprazole has no known major teratogenic risk, but proton pump inhibitors (PPIs) have weak association with congenital anomalies (odds ratio ~1.1–1.2). Overall, avoid in third trimester; use lowest effective dose in first and second trimesters if necessary. |
| Fetal Monitoring | Assess maternal renal function (serum creatinine, BUN) and hepatic function (LFTs) at baseline and periodically. Monitor for signs of gastrointestinal bleeding (CBC, stool guaiac). Fetal ultrasound to assess ductus arteriosus patency and amniotic fluid volume if prolonged use in third trimester. Monitor infant for adverse effects if breastfeeding. |
| Fertility Effects | Naproxen may impair female fertility through inhibition of prostaglandin synthesis, potentially delaying or preventing ovulation (reversible upon discontinuation). Esomeprazole has no known significant effect on fertility. Use in women attempting to conceive should be avoided or minimized. |
| Food/Dietary | Avoid high-fat meals as they may reduce the absorption and effectiveness of esomeprazole. Take on an empty stomach. Avoid alcohol, as it increases the risk of GI bleeding and stomach ulcers. |
| Clinical Pearls | Naproxen and esomeprazole magnesium is a fixed-dose combination used for the relief of symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis in patients at risk for developing NSAID-associated gastric ulcers. The esomeprazole component provides gastroprotection by inhibiting gastric acid secretion. Administer at least 30 minutes before meals for optimal absorption. Monitor renal function, blood pressure, and signs of GI bleeding. Avoid concurrent use with other NSAIDs, including COX-2 inhibitors, and with PPIs or H2RAs. Caution in patients with cardiovascular disease, history of GI ulceration, or on anticoagulants. |
| Patient Advice | Take this medication on an empty stomach at least 30 minutes before a meal. · Do not crush, chew, or split the tablet; swallow whole. · Avoid alcohol and other NSAIDs (including over-the-counter pain relievers like ibuprofen or aspirin) while on this medication. · Seek immediate medical attention if you experience black or bloody stools, vomiting blood, chest pain, or shortness of breath. · This medication may increase your risk of heart attack, stroke, or stomach bleeding, especially with long-term use. · Report any new or worsening joint pain, swelling, skin rash, or signs of kidney problems (e.g., decreased urination, swelling of ankles). |